{"id":"NCT01599104","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","officialTitle":"A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2012-05-15","resultsPosted":"2015-08-06","lastUpdate":"2015-10-16"},"enrollment":1161,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"LCZ696","otherNames":[]},{"type":"DRUG","name":"Olmesartan","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"LCZ696 200 mg","type":"EXPERIMENTAL"},{"label":"LCZ696 400 mg","type":"EXPERIMENTAL"},{"label":"Olmesartan 20 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension","primaryOutcome":{"measure":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)","timeFrame":"Baseline, 8 weeks","effectByArm":[{"arm":"LCZ696 200 mg","deltaMin":-18.21,"sd":0.702},{"arm":"LCZ696 400 mg","deltaMin":-20.18,"sd":0.704},{"arm":"Olmesartan 20 mg","deltaMin":-13.2,"sd":0.7}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":61,"countries":["Japan"]},"refs":{"pmids":["37026551"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":387},"commonTop":["NASOPHARYNGITIS"]}}